Currently we test and support the following browsers:
Please note that this is not intended to be an exhaustive list of browsers that support web standards, nor a test of browser compliance, nor a side-by-side comparison of various manufacturers’ browsers.
The quest to improve cure rates for children with acute myeloid leukemia (AML) got a boost recently from a St. Jude study that took a new look at an old drug.
St. Jude Children’s Research Hospital leads study showing that a drug withdrawn from the market in 2010 may enhance the effectiveness of bone marrow transplants for select pediatric leukemia patients. (Dr. Jeffrey Rubnitz)
St. Jude helps budding golfer Brennan Simkins through his battle with a rare form of acute myeloid leukemia, which required four bone marrow transplants.
They’ve boosted AML survival to an all-time high, but St. Jude investigators hunger for even sweeter statistics.
The first challenges surfaced in July 2007, when Jordan James was less than 2 days old. His mother Chancelly was recovering from a C-section delivery when Jordan, her only child, suffered a seizure. Within hours, both mother and child were in an ambulance speeding toward Memphis.
More individualized therapy and better supportive care helped push the survival for children with acute myeloid leukemia (AML) to 71 percent three years after diagnosis, according to new research led by St. Jude Children’s Research Hospital investigators and reported in the medical journal The Lancet Oncology.
Powerful but rare immune cells taken from a parent might provide a safe, effective and affordable approach to preventing cancer’s return in young patients with acute myeloid leukemia (AML), according to new St. Jude research.
Accurate prediction of treatment response and subsequent adjustment of therapy results in high remission rate and low treatment-related mortality.